GAB2 Amplification in Squamous Cell Lung Cancer of Non-Smokers.
10.3346/jkms.2017.32.11.1784
- Author:
Yu Rang PARK
1
;
Soo Hyeon BAE
;
Wonjun JI
;
Eul Ju SEO
;
Jae Cheol LEE
;
Hyeong Ryul KIM
;
Se Jin JANG
;
Chang Min CHOI
Author Information
1. Clinical Research Center, Asan Institute of Life Science, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
ArrayCGH;
Lung SCC;
Non-Smoker;
GAB2;
Proto-oncogene
- MeSH:
Biology;
Carcinoma, Squamous Cell;
Censuses;
Comparative Genomic Hybridization;
DNA;
Epithelial Cells*;
Genes, Neoplasm;
Genome;
Humans;
Incidence;
Lung Neoplasms*;
Lung*;
Neoplasms, Squamous Cell;
Proto-Oncogenes;
Smoke;
Smoking
- From:Journal of Korean Medical Science
2017;32(11):1784-1791
- CountryRepublic of Korea
- Language:English
-
Abstract:
Lung squamous cell cancer (SCC) is typically found in smokers and has a very low incidence in non-smokers, indicating differences in the tumor biology of lung SCC in smokers and non-smokers. However, the specific mutations that drive tumor growth in non-smokers have not been identified. To identify mutations in lung SCC of non-smokers, we performed a genetic analysis using arrays comparative genomic hybridization (ArrayCGH). We analyzed 19 patients with lung SCC who underwent surgical treatment between April 2005 and April 2015. Clinical characteristics were reviewed, and DNA was extracted from fresh frozen lung cancer specimens. All of copy number alterations from ArrayCGH were validated using The Cancer Genome Atlas (TCGA) copy number variation (CNV) data of lung SCC. We examined the frequency of copy number changes according to the smoking status (non-smoker [n = 8] or smoker [n = 11]). We identified 16 significantly altered regions from ArrayCGH data, three gain and four loss regions overlapped with the TCGA lung squamous cell carcinoma (LUSC) patients. Within these overlapped significant regions, we detected 15 genes that have been reported in the Cancer Gene census. We also found that the proto-oncogene GAB2 (11q14.1) was significantly amplified in non-smokers patients and vice versa in both ArrayCGH and TCGA data. Immunohistochemical analyses showed that GAB2 protein was relatively upregulated in non-smoker than smoker tissues (37.5% vs. 9.0%, P = 0.007). GAB2 amplification may have an important role in the development of lung SCC in non-smokers. GAB2 may represent a potential biomarker for lung SCC in non-smokers.
